Cited by 479Glaucoma and retinal disordersRetinal Diseases and TreatmentsRetinal Imaging and Analysis

Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma

Open access
Howell, Gareth R., Macalinao, Danilo G., Sousa, Gregory L., Walden, Michael, Soto, Ileana, Kneeland, Stephen C., Barbay, Jessica M., King, Benjamin L. +7 more·2011·Journal of Clinical Investigation

Abstract

Glaucoma is one of the most common neurodegenerative diseases. Despite this, the earliest stages of this complex disease are still unclear. This study was specifically designed to identify early stages of glaucoma in DBA/2J mice. To do this, we used genome-wide expression profiling of optic nerve head and retina and a series of computational methods. Eyes with no detectable glaucoma by conventional assays were grouped into molecularly defined stages of disease using unbiased hierarchical clustering. These stages represent a temporally ordered sequence of glaucoma states. We then determined networks and biological processes that were altered at these early stages. Early-stage expression changes included upregulation of both the complement cascade and the endothelin system, and so we tested the therapeutic value of separately inhibiting them. Mice with a mutation in complement component 1a (C1qa) were protected from glaucoma. Similarly, inhibition of the endothelin system with bosentan, an endothelin receptor antagonist, was strongly protective against glaucomatous damage. Since endothelin 2 is potently vasoconstrictive and was produced by microglia/macrophages, our data provide what we believe to be a novel link between these cell types and vascular dysfunction in glaucoma. Targeting early molecular events, such as complement and endothelin induction, may provide effective new treatments for human glaucoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci44646

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a mouse model of glaucoma, C1q and C3 are highly upregulated and deposited on retinal synapses, and C1q deficiency or microglial inactivation with minocycline provides significant neuroprotection.

    “Indeed, in a mouse model of glaucoma, a neurodegenerative disease associated with RGC loss and gliosis, C1q and C3 are highly upregulated and deposited on retinal synapses and C1q deficiency or microglial ‘inactivation’ with minocycline provide significant neuroprotection (Howell et al., 2011; Steele et al., 2006; Stevens et al., 2007).”

    From Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner (2012) · cites this paper as Howell et al., 2011

    The research article (p. 6) reports early retinal upregulation of C1qa, C1qb and C1qc and says C1qa localizes to retinal synapses. Table 1 (p. 7) and Figure 8 (p. 11) show substantial protection in C1qa-deficient mice. Our copy does not establish C3 deposition on retinal synapses or neuroprotection from microglial inactivation with minocycline. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [41]Krishnamoorthy RR, Rao VR, Dauphin R, Prasanna G, Johnson C, Yorio T. Role of the ETB receptor in retinal ganglion cell death in glaucoma. Can J Physiol Pharmacol . 2008;86(6):380-393.

Cited by

Sorted by citations

Authors
Howell, G. R., Macalinao, D. G., Sousa, G. L., Walden, M., Soto, I., Kneeland, S. C., Barbay, J. M., King, B. L., Marchant, J. K., Hibbs, M., Stevens, B., Barres, B. A., Clark, A. F., Libby, R. T., & John, S. W. M.
Affiliations
  • Howard Hughes Medical Institute (US)
  • Jackson Laboratory (US)
  • Mount Desert Island Biological Laboratory (US)
  • Tufts University (US)
  • Harvard University (US)
  • Stanford University (US)
  • University of North Texas Health Science Center (US)
  • University of Rochester (US)
Corresponding author
John, Simon W.M.
Venue
Journal of Clinical Investigation
Published
2011-04-01
Volume
121
Issue
4
Pages
1429-1444
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1983740408
Cited by
473
References
77
Citations by year
2026: 25 · 2025: 28 · 2024: 20 · 2023: 46 · 2022: 43 · 2021: 34 · 2020: 39 · 2019: 26 · 2018: 24 · 2017: 33 · 2016: 29 · 2015: 35 · 2014: 24 · 2013: 28 · 2012: 28
FWCI
26.40
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • American Health Assistance Foundation
  • Research to Prevent Blindness
  • National Institutes of Health (NIH T32, EY011721)
  • National Eye Institute (EY018606, R29EY011721, R01EY018606, R01EY011721, EY011721, F32EY014515)
  • National Institute of Neurological Disorders and Stroke (T32 NS51112-05, T32NS051112)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
glaucoma, early-stage disease, complement system, endothelin system, endothelin receptor antagonism, bosentan, C1QA, optic nerve head, retina, microglia/macrophages, vascular dysfunction, disease progression, therapeutic target, DBA/2J mice
MeSH terms
Bosentan, Animals, Disease Models, Animal, Female, Glaucoma, Humans, Mice, Inbred DBA, Mice, Mutant Strains, Optic Nerve, Retina, Sulfonamides, Signal Transduction, Up-Regulation, Complement C1q, Cluster Analysis, Endothelin-2, Gene Expression Profiling, Mice, Endothelin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review